{"id":"https://openalex.org/W4308385286","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","title":"1078 Conditionally activatable interferon-alpha 2b improves tolerability and exhibits preferential activity in tumors","display_name":"1078 Conditionally activatable interferon-alpha 2b improves tolerability and exhibits preferential activity in tumors","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308385286","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1078"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1078","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1120.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1120.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102822234","display_name":"Alexey Berezhnoy","orcid":"https://orcid.org/0000-0002-7886-5181","observed_orcids":["https://orcid.org/0000-0002-7886-5181"]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexey Berezhnoy","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hsin Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hsin Wang","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012991076","display_name":"Nicole Lapuyade","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Lapuyade","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Na Cai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Na Cai","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014884453","display_name":"Carol LePage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carol LePage","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Winter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Winter","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017079810","display_name":"Michael Krimm","orcid":"https://orcid.org/0000-0002-6804-999X","observed_orcids":["https://orcid.org/0000-0002-6804-999X"]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Krimm","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kenneth Wong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Wong","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Robert Dunn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Dunn","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sean McAlister","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean McAlister","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022076310","display_name":"Leila M. Boustany","orcid":"https://orcid.org/0000-0002-8377-5797","observed_orcids":["https://orcid.org/0000-0002-8377-5797"]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leila Boustany","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005982696","display_name":"Madan Paidhungat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madan Paidhungat","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036398076","display_name":"Marcia P. Belvin","orcid":"https://orcid.org/0000-0002-4447-9629","observed_orcids":["https://orcid.org/0000-0002-4447-9629"]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcia Belvin","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012245136","display_name":"Erwan Le Scolan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erwan Le Scolan","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104384780","display_name":"Dylan Daniel","orcid":"https://orcid.org/0000-0003-0520-4427","observed_orcids":["https://orcid.org/0000-0003-0520-4427"]},"institutions":[{"id":"https://openalex.org/I4210145361","display_name":"CytomX Therapeutics (United States)","ror":"https://ror.org/03c06gm48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210145361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dylan Daniel","raw_affiliation_strings":["CytoX Therapeutics, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CytoX Therapeutics, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210145361"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210145361"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1120","last_page":"A1120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4088999927043915,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4088999927043915,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.365200012922287,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.08910000324249268,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.9369999766349792},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8230000138282776},{"id":"https://openalex.org/keywords/tumor-associated-proteases","display_name":"tumor-associated proteases","score":0.8579999804496765},{"id":"https://openalex.org/keywords/mask-wearing","display_name":"masking","score":0.3630000054836273},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7160000205039978},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.703000009059906},{"id":"https://openalex.org/keywords/immune-cell-activation","display_name":"immune cell activation","score":0.6690000295639038},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6729999780654907},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7289999723434448},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.3569999933242798},{"id":"https://openalex.org/keywords/cytokine-therapy","display_name":"cytokine therapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6290000081062317},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6827619075775146},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.6735039949417114},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6582759022712708},{"id":"https://openalex.org/C182220744","wikidata":"https://www.wikidata.org/wiki/Q7251226","display_name":"Proteases","level":3,"score":0.6048147678375244},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5924499034881592},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5650831460952759},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.504705548286438},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.49810242652893066},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.46165525913238525},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4033038318157196},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3094456195831299},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.25072532892227173},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.21626517176628113},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.10513386130332947},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.06252476572990417}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.1078","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1120.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1078","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1078","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1120.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308385286.pdf","grobid_xml":"https://content.openalex.org/works/W4308385286.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282980580","https://openalex.org/W4388084469","https://openalex.org/W3212501176","https://openalex.org/W4308398399","https://openalex.org/W3214245801","https://openalex.org/W7148728483","https://openalex.org/W7148810068","https://openalex.org/W4409629443","https://openalex.org/W4362543558","https://openalex.org/W3181719380"],"abstract_inverted_index":{"Background":[0],"Despite":[1],"its":[2,11,33,71,86,147,220],"potential,":[3],"the":[4,41,50,107,110,150,162,195,216,240,244,259],"toxicity":[5],"of":[6,81,103,124,152,161,192,215,228,243,248],"interferon":[7,125],"alpha":[8],"has":[9],"limited":[10],"clinical":[12],"use.":[13],"CytomX":[14],"proprietary":[15],"Probody\u00ae":[16],"Therapeutics":[17],"(Pb-Tx)":[18],"technology":[19,78],"allowed":[20],"us":[21],"to":[22,46,65,136,154,169,219,258,279,294,308,316],"create":[23],"a":[24,59,82,104,305],"conditionally":[25],"active":[26,87],"IFN-a2b":[27],"(Pb-IFN-a2b)":[28],"with":[29,318],"minimal":[30],"activity":[31,48,80,160,183,289],"in":[32,40,49,54,127,143,164,199,203,210,254,290],"prodrug":[34,37],"form.":[35],"The":[36,75],"is":[38,98,167],"activated":[39],"tumor":[42,113,138,177,231],"microenvironment":[43],"(TME),":[44],"leading":[45],"preferential":[47],"TME":[51],"but":[52,201],"not":[53,202],"healthy":[55],"tissues.":[56],"Pb-IFN-a2b":[57,117,163,225,265,283],"demonstrated":[58,118,180,212,266],"substantially":[60],"enhanced":[61,187,213],"tolerability":[62,214,286],"profile":[63],"compared":[64,218,257,293],"standard":[66],"IFN":[67,249,296],"therapy":[68],"without":[69],"compromising":[70],"antitumor":[72,182,288],"effects.":[73],"Methods":[74],"Pb-Tx":[76],"platform":[77],"attenuates":[79],"molecule":[83,108,196,217],"by":[84,112,188,194,331],"blocking":[85],"regions":[88],"through":[89],"affinity":[90],"or":[91,122,140,170],"steric":[92],"interference.":[93],"Such":[94],"blockade,":[95],"termed":[96],"masking,":[97],"reversed":[99],"upon":[100],"proteolytic":[101],"cleavage":[102],"linker":[105],"between":[106],"and":[109,129,271,287,329,336],"mask":[111],"associated":[114],"proteases.":[115],"Results":[116],"considerable":[119],"reduction":[120],"(1000-fold":[121],"more)":[123],"signaling":[126,250],"vitro":[128,144],"significantly":[130],"reduced":[131],"immune":[132,157],"cell":[133],"activation.":[134],"Exposure":[135],"viable":[137],"tissues":[139],"tumor-associated":[141],"proteases":[142],"fully":[145],"restored":[146],"bioactivity,":[148],"including":[149],"ability":[151],"Pb-IFN":[153,179],"stimulate":[155],"tumor-infiltrating":[156],"cells.":[158],"Antitumor":[159],"xenograft":[165],"studies":[166,208,292],"equal":[168],"greater":[171],"than":[172],"Peg-IFN-\u03b12b.":[173],"In":[174,223,262],"syngeneic":[175],"mouse":[176],"models,":[178],"significant":[181],"that":[184,237],"was":[185,197,272],"further":[186],"PD-(L)1":[189],"blockade.":[190],"Activation":[191],"lymphocytes":[193],"observed":[198],"tumors":[200],"secondary":[204],"lymphoid":[205],"organs.":[206],"Toxicology":[207],"performed":[209],"hamsters":[211],"unmasked":[221,245,260],"control.":[222,246,261],"addition,":[224],"suppressed":[226],"growth":[227],"hamster":[229],"melanoma":[230],"model":[232],"RPMI1846":[233],"at":[234,275],"dose":[235,242],"levels":[236],"were":[238,251,327],"above":[239],"tolerated":[241,274],"Biomarkers":[247],"greatly":[252],"attenuated":[253],"non-human":[255],"primates":[256],"cynomolgus":[263],"monkey,":[264],"linear":[267],"pharmacokinetics,":[268],"extended":[269],"half-life,":[270],"well":[273],"weekly":[276],"doses":[277],"up":[278],"60":[280],"mg/kg.":[281],"Conclusions":[282],"shows":[284],"improved":[285],"preclinical":[291],"traditional":[295],"treatment.":[297],"These":[298],"data":[299],"support":[300],"Probody":[301],"cytokine":[302],"therapeutics":[303],"as":[304],"promising":[306],"addition":[307],"current":[309],"immunotherapy":[310],"regimens,":[311],"potentially":[312],"expanding":[313],"their":[314],"benefits":[315],"patients":[317],"typically":[319],"unresponsive":[320],"tumors.":[321],"Ethics":[322],"Approval":[323],"All":[324],"animal":[325],"experiments":[326],"reviewed":[328],"approved":[330],"CytomX\u2019s":[332],"Institutional":[333],"Animal":[334],"Care":[335],"Use":[337],"Committee":[338],"(IACUC":[339],"Protocol":[340],"AP303).":[341]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2022-11-11T00:00:00"}